Marc Fortin

Marc Fortin

Auto-generated profile, based on publicly available information

Marc Fortin

Department of Pulmonology and Thoracic Surgery, Quebec Heart and Lung Institute, Laval University, Quebec, Québec, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MFMarc Fortin
Marc Fortin
MLMoishe Liberman
Moishe Liberman
ADAntoine Delage
Antoine Delage
GDGeneviève Dion
Geneviève Dion
SMSimon Martel
Simon Martel
SPSteeve Provencher
Steeve Provencher
Rationale: Transbronchial cryobiopsy (TBCB) for the diagnosis of interstitial lung disease (ILD) has shown promising results, but prospective studies with matched surgical lung biopsy (SLB) have yielded conflicting results. Objectives: We aimed to assess within- and between-center diagnostic agreement between TBCB and SLB at both the histopathologic and multidisciplinary discussion (MDD) levels in patients with diffuse ILD. Methods: In a multicenter prospective study, we performed matched TBCB and SLB in patients referred for SLB. After a blinded review by three pulmonary pathologists, all cases were reviewed by three independent ILD teams in an MDD. MDD was performed first with TBCB, then with SLB in a second session. Within-center and between-center diagnostic agreement was evaluated using percentages and correlation coefficients. Measurements and Main Results: Twenty patients were recruited and underwent contemporaneous TBCB and SLB. Within-center diagnostic agreement between TBCB–MDD and SLB–MDD was reached in 37 of the 60 (61.7%) paired observations, resulting in a Cohen’s κ value of 0.46 (95% confidence interval [CI], 0.29–0.63). Diagnostic agreement increased among high-confidence or definitive diagnoses on TBCB–MDD (21 of 29 [72.4%]), but not significantly, and was more likely among cases with SLB–MDD diagnoses of idiopathic pulmonary fibrosis than fibrotic hypersensitivity pneumonitis (13 of 16 [81.2%] vs. 16 of 31 [51.6%]; P = 0.047). Between-center agreement for cases was markedly higher for SLB–MDD (κ = 0.71 [95% CI, 0.52–0.89]) than TBCB–MDD (κ = 0.29 [95% CI, 0.09–0.49]). Conclusions: This study demonstrated moderate TBCB–MDD and SLB–MDD diagnostic agreement for ILD, while between-center agreement was fair for TBCB–MDD and substantial for SLB–MDD. Clinical trial registered with www.clinicaltrials.gov (NCT 02235779).

14 June 2020 in Respirology
Verified
Journal Article
Closed access
PDF file
MFMarc Fortin
Marc Fortin
LYLonny Yarmus
Lonny Yarmus
ERErino Angelo Rendina
Erino Angelo Rendina
SRSamaan Rafeq
Samaan Rafeq
RARafael Andrade
Rafael Andrade
MLMoishe Liberman
Moishe Liberman

1 December 2021 in Chest
Verified
Journal Article
Closed access
JGJulien Guinde
Julien Guinde
EBEtienne Bourdages-Pageau
Etienne Bourdages-Pageau
MCMarie-May Collin-Castonguay
Marie-May Collin-Castonguay
LLLaurie Laflamme
Laurie Laflamme
ALAlexandra Lévesque-Laplante
Alexandra Lévesque-Laplante
MFMarc Fortin
Marc Fortin

1 January 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
PDPatrice Desmeules
Patrice Desmeules
MDMatthieu Dusselier
Matthieu Dusselier
CBCédrik Bouffard
Cédrik Bouffard
JBJosée Bafaro
Josée Bafaro
MFMarc Fortin
Marc Fortin
Philippe JoubertPhilippe Joubert
Philippe Joubert
Biomarker testing is key for non-small cell lung cancer (NSCLC) management and plasma based next-generation sequencing (NGS) is increasingly characterized as a non-invasive alternative. This study aimed to evaluate the value of complementary circulating tumor DNA (ctDNA) NGS on tissue single-gene testing (SGT). Ninety-one advanced stage NSCLC patients with tumor genotyping by tissue SGT (3 genes) followed by ctDNA (38 genes amplicon panel) were included. ctDNA was positive in 47% (n = 43) and identified a targetable biomarker in 19 patients (21%). The likelihood of positivity on ctDNA was higher if patients had extra-thoracic disease (59%) or were not under active treatment (59%). When compared to SGT, ctDNA provided additional information in 41% but missed a known alteration in 8%. Therapeutic change for targeted therapy based on ctDNA occurred in five patients (5%), while seven patients with missed alterations on ctDNA had EGFR mutations or ALK fusions. The median turnaround time of ctDNA was 10 days (range 6–25), shorter (p = 0.002) than the cumulative delays for the tissue testing trajectory until biomarker availability (13 d; range 7–1737). Overall, the results from this study recapitulate the potential and limitations of ctDNA when used complementarily to tissue testing with limited biomarker coverage.

1 July 2024 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
MFMarc Fortin
Marc Fortin
DDDel R Dorscheid
Del R Dorscheid
MLMoishe Liberman
Moishe Liberman
SMSimon Martel
Simon Martel
TSTawimas Shaipanich
Tawimas Shaipanich
Purpose: Chronic bronchitis (CB), a chronic obstructive pulmonary disease (COPD) phenotype defined by persistent mucus hypersecretion and cough, is associated with poor quality of life, exacerbations, and lung function impairment. Bronchial Rheoplasty (BR) delivers non-thermal pulsed electric fields to airway epithelium and submucosa. Preliminary studies demonstrated reduced airway goblet cell hyperplasia and symptom improvement in response to BR. This study aimed to further assess the safety and clinical feasibility of BR in the setting of CB. Patients and Methods: This 3-center, single-arm study evaluated the safety and feasibility of BR in Canadian patients. The major inclusion criteria were the sum of CAT first 2 questions (cough and mucus) ≥ 7 out of 10 and FEV1 ≥ 30% predicted. Right-sided airways were treated first; left, 1 month later. Serious adverse events (SAEs) were tabulated through 12 months. Outcomes were evaluated using the SGRQ and CAT. Results: Ten patients with CB were enrolled and followed for 12 months. The BR procedure was successful in all patients (mean age 69 ± 5.8 years, post-BD FEV1 77.1 ± 28.3, SGRQ 56.2 ± 8.8, CAT 25.4 ± 4.7). Only one SAE, a COPD exacerbation 13 days following the BR procedure, was considered device related. No additional SAEs occurred through 12 months, and 90% of the patients were CAT responders (≥ 2-point improvement) at 3 and 6 months. Similar results were observed in SGRQ. Conclusion: BR was safe and well-tolerated. Meaningful symptom improvement was observed through 12 months, suggesting BR may be a viable treatment option for patients with CB.

1 September 2020 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
MCMarie-May Collin-Castonguay
Marie-May Collin-Castonguay
JGJulien Guinde
Julien Guinde
LLLaurie Laflamme
Laurie Laflamme
SMSabrina Marcoux
Sabrina Marcoux
MFMarc Fortin
Marc Fortin
Previous studies evaluating staging methods of lung cancer have focused on mediastinal disease. We explored the added value of endoscopic techniques after PET scan in the evaluation of N1 nodal stations in 276 patients with a radiologically normal mediastinum demonstrating a potential stage shift in 20% of patients.